Biomarkers for immunotherapy toxicity: are cytokines the answer?

Biomarkers for immunotherapy toxicity: are cytokines the answer?
Clin Cancer Res. 2018 Dec 26;:
Authors: Johnson DB, Balko JM
Abstract
Immune checkpoint inhibitors induce durable responses in some advanced cancer patients, but may simultaneously trigger auto-inflammatory immune-related adverse events (irAEs). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor-host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment.
PMID: 30587548 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 26, 2018 Category: Cancer & Oncology Authors: Johnson DB, Balko JM Tags: Clin Cancer Res Source Type: research